Kmart Australia and toy manufacturer Headstart International have hit back at Jellycat in a suit claiming they are selling ‘Bashful Bunny’ knockoffs, arguing the shape […]
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in […]
The competition regulator has proposed to deny authorisation for a patent settlement that sought to permit early entry of generic drugs. Whether the companies involved […]
The Federal Court has signed off on a settlement between two US biotech companies that ends a dispute over the companies’ ‘Access’ trade marks in […]
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three […]
A judge has questioned GME’s pursuit of additional damages in its intellectual property lawsuit against Japan’s Uniden that alleges the upcoming launch by the wireless […]
King & Wood Mallesons has appointed a former Corrs Chambers Westgarth partner to join its intellectual property practice in Melbourne. Former head of intellectual property […]
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to […]
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime […]
A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown […]